AU2014202182A1 - Crosslinked gelatin support and support for controlled release of physiologically active substance using the same - Google Patents
Crosslinked gelatin support and support for controlled release of physiologically active substance using the same Download PDFInfo
- Publication number
- AU2014202182A1 AU2014202182A1 AU2014202182A AU2014202182A AU2014202182A1 AU 2014202182 A1 AU2014202182 A1 AU 2014202182A1 AU 2014202182 A AU2014202182 A AU 2014202182A AU 2014202182 A AU2014202182 A AU 2014202182A AU 2014202182 A1 AU2014202182 A1 AU 2014202182A1
- Authority
- AU
- Australia
- Prior art keywords
- crosslinked gelatin
- support
- active substance
- physiologically active
- crosslinked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010010803 Gelatin Proteins 0.000 title claims abstract description 169
- 229920000159 gelatin Polymers 0.000 title claims abstract description 169
- 235000019322 gelatine Nutrition 0.000 title claims abstract description 169
- 235000011852 gelatine desserts Nutrition 0.000 title claims abstract description 169
- 239000008273 gelatin Substances 0.000 title claims abstract description 168
- 239000013543 active substance Substances 0.000 title claims abstract description 85
- 238000013270 controlled release Methods 0.000 title claims abstract description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 230000000717 retained effect Effects 0.000 claims abstract description 13
- 239000002245 particle Substances 0.000 claims description 50
- 238000000354 decomposition reaction Methods 0.000 claims description 38
- 238000004132 cross linking Methods 0.000 description 46
- 238000005259 measurement Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000003102 growth factor Substances 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000001276 controlling effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 239000002504 physiological saline solution Substances 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- 238000006065 biodegradation reaction Methods 0.000 description 8
- 239000000049 pigment Substances 0.000 description 8
- 239000003431 cross linking reagent Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000000733 zeta-potential measurement Methods 0.000 description 6
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229960000907 methylthioninium chloride Drugs 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000010102 embolization Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000861 blow drying Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012897 dilution medium Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Laminated Bodies (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013-089142 | 2013-04-22 | ||
| JP2013089142A JP2014210756A (ja) | 2013-04-22 | 2013-04-22 | 架橋ゼラチン担体およびそれを用いた生理活性物質徐放担体 |
| JP2013089143A JP2014210757A (ja) | 2013-04-22 | 2013-04-22 | 架橋ゼラチン担体およびそれを用いた生理活性物質徐放担体 |
| JP2013-089143 | 2013-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2014202182A1 true AU2014202182A1 (en) | 2014-11-06 |
Family
ID=50489016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014202182A Abandoned AU2014202182A1 (en) | 2013-04-22 | 2014-04-22 | Crosslinked gelatin support and support for controlled release of physiologically active substance using the same |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9351934B2 (https=) |
| EP (1) | EP2796127A1 (https=) |
| KR (1) | KR20140126264A (https=) |
| CN (1) | CN104109252A (https=) |
| AU (1) | AU2014202182A1 (https=) |
| CA (1) | CA2849472A1 (https=) |
| IN (1) | IN2014CH02034A (https=) |
| RU (1) | RU2014115991A (https=) |
| TW (1) | TW201517920A (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11207258B2 (en) | 2016-01-25 | 2021-12-28 | Suntory Holdings Limited | Capsule containing functional substance and method for manufacturing said capsule |
| CN110876812A (zh) * | 2019-12-06 | 2020-03-13 | 赛克赛斯生物科技股份有限公司 | 明胶海绵栓塞剂及其制备方法和应用、治疗血管疾病或肿瘤的药物 |
| CN111269444A (zh) * | 2020-01-22 | 2020-06-12 | 苏州新丝原生物科技有限公司 | 一种交联微球及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998003203A1 (fr) | 1996-07-19 | 1998-01-29 | Yamanouchi Pharmaceutical Co., Ltd. | Particules poreuses insolubles dans l'eau, constituees de substances biocompatibles et leur procede de production |
| DE60229399D1 (de) | 2001-07-18 | 2008-11-27 | Medgel Corp | Hgf-hydrogel-zubereitungen mit verzögerter freisetzung |
| JP2004115413A (ja) * | 2002-09-25 | 2004-04-15 | Yasuhiko Tabata | 冠状動脈狭窄または閉塞治療用徐放性製剤 |
| US20110229580A1 (en) | 2010-03-22 | 2011-09-22 | Indian Institute of Technology Bombay, School of Biosciences and Bioengineering | Compositions and methods for nano-in-micro particles |
-
2014
- 2014-04-17 CA CA2849472A patent/CA2849472A1/en not_active Abandoned
- 2014-04-18 US US14/256,134 patent/US9351934B2/en active Active
- 2014-04-21 IN IN2034CH2014 patent/IN2014CH02034A/en unknown
- 2014-04-21 RU RU2014115991/15A patent/RU2014115991A/ru not_active Application Discontinuation
- 2014-04-22 CN CN201410163492.6A patent/CN104109252A/zh active Pending
- 2014-04-22 EP EP14165440.0A patent/EP2796127A1/en not_active Withdrawn
- 2014-04-22 AU AU2014202182A patent/AU2014202182A1/en not_active Abandoned
- 2014-04-22 TW TW103114560A patent/TW201517920A/zh unknown
- 2014-04-22 KR KR1020140047889A patent/KR20140126264A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014115991A (ru) | 2015-10-27 |
| US9351934B2 (en) | 2016-05-31 |
| KR20140126264A (ko) | 2014-10-30 |
| CN104109252A (zh) | 2014-10-22 |
| CA2849472A1 (en) | 2014-10-22 |
| US20140316013A1 (en) | 2014-10-23 |
| IN2014CH02034A (https=) | 2015-07-03 |
| EP2796127A1 (en) | 2014-10-29 |
| TW201517920A (zh) | 2015-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | pH-Controlled drug delivery with hybrid aerogel of chitosan, carboxymethyl cellulose and graphene oxide as the carrier | |
| Wang et al. | Preparation and characterization of agarose hydrogel nanoparticles for protein and peptide drug delivery | |
| CN115192543B (zh) | 载脂溶性色素纳米粒的制备方法 | |
| CN107595809A (zh) | 一种玉米醇溶蛋白纳米包埋缓释填充物及其制备方法 | |
| US9351934B2 (en) | Crosslinked gelatin support and support for controlled release of physiologically active substance using the same | |
| Jyothi et al. | Microsponges: a promising novel drug delivery system | |
| Mahalekshmi et al. | Recent advancement of nanosponges in pharmaceutical formulation for drug delivery systems | |
| Taşkın Çakıcı | Nano TiO2-doped sodium alginate/hydroxypropyl methylcellulose synthesis of bionanocomposite membrane and its use in controlled release of anti-cancer drug 5-fluorouracil | |
| Çakıcı | Nano TiO2-doped sodium alginate/hydroxypropyl methylcellulose synthesis of bionanocomposite membrane and its use in controlled release of anti-cancer drug 5-fluorouracil | |
| Pinlaor et al. | Solid dispersion improves release of curcumin from nanoparticles: potential benefit for intestinal absorption | |
| Rani et al. | Characterization and biodegradation studies for interpenetrating polymeric network (IPN) of chitosan-amino acid beads | |
| Upadhye et al. | Nanosponges: An innovative approach for targeted drug delivery system | |
| KR20090107795A (ko) | 서방성 마이크로캡슐의 제조방법 및 그로 제조된마이크로캡슐 | |
| JP2014218464A (ja) | 均一分散可能な架橋ゼラチン粒子集合体 | |
| CN104224688A (zh) | 负载纳米药物的丙烯酸酯化透明质酸水凝胶及其制备方法 | |
| JP2014210757A (ja) | 架橋ゼラチン担体およびそれを用いた生理活性物質徐放担体 | |
| Biswas et al. | Gel based formulations in oral controlled release drug delivery | |
| KR0164462B1 (ko) | 알긴산염 초미세구립자의 제조방법 | |
| Arulanandraj et al. | Nanotechnological approach to enhance the stability and bioavailability of the herbal drug" Murva". | |
| M. Balcao et al. | Development and characterization of a gel formulation integrating microencapsulated nitrofurazone | |
| Afifi et al. | Montmorillonite-Chitosan as a Biocomposite Encapsulation for Ibuprofen in Drug Release, J | |
| JP2014210756A (ja) | 架橋ゼラチン担体およびそれを用いた生理活性物質徐放担体 | |
| Milenkova et al. | Curcumin loaded casein submicron-sized gels as drug delivery systems | |
| Delfiya et al. | In vitro release kinetics of spray dried curcumin-loaded egg albumin microparticles | |
| WO2015020139A1 (ja) | ナノ粒子及びナノ粒子組成物並びにその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |